These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29998996)

  • 1. Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease.
    Ono Y; Takamatsu H; Inoue M; Mabuchi Y; Ueda T; Suzuki T; Kurabayashi M
    Drug Discov Ther; 2018; 12(3):154-160. PubMed ID: 29998996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
    Nakano Y; Mizuno T; Niwa T; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Murotani K; Waseda K; Amano T
    Int Heart J; 2018 Jan; 59(1):105-111. PubMed ID: 29332911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Long-Term Use of Tolvaptan in Patients With Heart Failure and Chronic Kidney Disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Imai R; Ozaki Y; Watanabe T; Teraoka T; Watarai M; Murohara T
    Circ J; 2017 Oct; 81(11):1736-1738. PubMed ID: 28883217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal ultrasonography predicts worsening renal function in patients with heart failure under tolvaptan administration.
    Tanaka N; Furukawa Y; Maeda T; Ishihara H; Dan K; Teramura M; Ichihashi K; Takase T; Takahashi Y; Tsuzura D; Shinoda A; Fujii M; Okada H; Itabashi F; Teramoto T
    ESC Heart Fail; 2024 Aug; 11(4):1911-1918. PubMed ID: 38468548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan.
    Fujioka K; Mizuno S; Ichise T; Matsui T; Hirase H; Yamaguchi M; Aoyama T; Yamagishi M; Fujino N; Kawashiri MA; Hayashi K
    Ther Adv Cardiovasc Dis; 2019; 13():1753944718819064. PubMed ID: 30803403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan for Heart Failure in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
    Sen J; Chung E; McGill D
    Heart Lung Circ; 2018 Aug; 27(8):928-939. PubMed ID: 29602756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with long-term administration of tolvaptan to patients with acute decompensated heart failure.
    Kiuchi S; Fujii T; Hisatake S; Kabuki T; Takashi O; Dobashi S; Ikeda T
    Drug Discov Ther; 2017 Jul; 11(3):133-139. PubMed ID: 28626112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.
    Kiuchi S; Ikeda T
    Intern Med; 2019 Feb; 58(4):471-475. PubMed ID: 30210135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suitable Dose of Long-Term Tolvaptan to Reduce Heart Failure Rehospitalizations.
    Nishino M; Tanaka A; Kawanami S; Sugae H; Ukita K; Kawamura A; Nakamura H; Matsuhiro Y; Yasumoto K; Tsuda M; Okamoto N; Matsunaga-Lee Y; Yano M; Egami Y; Tanouchi J
    Int Heart J; 2022; 63(1):85-90. PubMed ID: 35095082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.
    Ikeda S; Ohshima K; Miyazaki S; Kadota H; Shimizu H; Ogimoto A; Hamada M
    ESC Heart Fail; 2017 Nov; 4(4):614-622. PubMed ID: 29154417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure.
    Nakao K; Horio T; Yoshimura R; Fujiwara R; Matsuoka Y; Yokouchi G; Nakamura H; Sakamoto Y; Fujimoto K; Izumiya Y; Yoshiyama M; Kasayuki N
    Heart Vessels; 2021 Aug; 36(8):1175-1182. PubMed ID: 33580283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
    Ikeda Y; Inomata T; Kida K; Shibagaki Y; Sato N; Izumi T; Ako J;
    Heart Vessels; 2019 Mar; 34(3):442-451. PubMed ID: 30259172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study.
    Minami S; Hamano T; Iwatani H; Mizui M; Kimura Y; Isaka Y
    Clin Exp Nephrol; 2018 Jun; 22(3):550-561. PubMed ID: 29052786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease.
    Amioka M; Sanada R; Matsumura H; Kinoshita H; Sairaku A; Morishima N; Nakano Y
    Int J Cardiol; 2023 Jan; 370():294-299. PubMed ID: 36174820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　- Results From the K-STAR Study.
    Inomata T; Ikeda Y; Kida K; Shibagaki Y; Sato N; Kumagai Y; Shinagawa H; Ako J; Izumi T;
    Circ J; 2017 Dec; 82(1):159-167. PubMed ID: 28835586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.